Smart Money Ratings For 20 Most Undervalued Stocks

Page 18 of 18

1. Immunovant, Inc. (NASDAQ:IMVT)

Insider Transaction: 19.69%

Upside Potential: 253.11%

Forward P/E: 0.00

Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biotechnology company headquartered in New York. The company specializes in developing targeted therapies for autoimmune diseases. Its flagship product, IMVT-1402, is an FcRn inhibitor that helps treat conditions like myasthenia gravis and thyroid eye disease. Immunovant, Inc. (NASDAQ:IMVT) signifies a differentiated safety and efficacy profile in which trial progression takes priority, but investor confidence, regulatory approval timelines, and therapeutic market expansion have some level of influence on the company’s growth. The company has yet to generate any profit as it is still in the development phase.

The company’s value is 12.19% above its 52-week low, showing upward movement. Although Immunovant, Inc. (NASDAQ:IMVT) reported a significant net loss of $111.1 million for the quarter ending December 31, 2024, the company stands strong in its cash position with a value of approximately $825 million. In addition to funding ongoing pivotal trials, this substantial capital allows the company to expand R&D efforts across ten planned indications. The company is also making significant progress with its lead asset IMVT-1402. The asset has cleared six Investigational New Drug (IND) applications. It has entered pivotal studies in Graves’ disease and difficult-to-treat rheumatoid arthritis, increasing its potential to generate significant revenue in the upcoming years.

Insider buying signals internal optimism, jumping to 19.69% in the past six months. Hedge fund involvement is strong, with 35 participants holding on to the company’s stakes. The forward P/E ratio of 0.00 indicates that the market valuation has not yet considered the company’s future growth potential. With a staggering upside potential of 253.11%, Immunovant, Inc. (NASDAQ:IMVT) stands out as the most undervalued in our list, with bullish sentiment across the board.

Immunovant, Inc. (NASDAQ:IMVT) ranks first among the smart money ratings for the 20 most undervalued stocks. While we acknowledge the potential of IMVT, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IMVT but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks To Invest In According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 18 of 18